MBX · MBX Biosciences, Inc.

Track MBX — free

$63.00 -3.39 (-5.11%) At close · Aug 28

Russell 2000 member Rebalance outlook locked

Market Cap

$3.20B

48.16M

Up next

Next earnings call

Oct 20, 2026 Est · unconfirmed · in 7 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 6, 2026

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 14.4 · calm Equity put/call 0.62

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +58%

above

Price vs 50-day avg +2%

above

RSI (14) 46

neutral

MACD trend Negative

52-week position 87%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −4%

trailing

6-month return +125%

trailing

YTD return +100%

this year

Relative strength +112%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $62 › 200d $40 — 50d above 200d

Institutional flow Accumulating

+11% holders QoQ · +40 funds added

Insider flow Distributing

Net -$24.3K over 90 days · 100% sells

Short interest Falling

10.28% of float · ▼ -4.6% MoM · 11.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

176 holders — near 2-yr high, broad support

Squeeze score 71

high risk · 0–100

Fundamentals

Fair

EPS growth +59%

Y/Y

Free cash flow $-81.9M

Quant / Vol

risk profile

Very High

Volatility 131%

annualized · 1-yr

Max drawdown −38%

past year

ATR 5.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+58% Bullish

Price vs 50-day avg

+2% Bullish

RSI (14)

46 Neutral

MACD trend

Negative Bearish

52-week position

87% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $62 › 200d $40 — 50d above 200d

Institutional flow Accumulating

+11% holders QoQ · +40 funds added

Insider flow Distributing

Net -$24.3K over 90 days · 100% sells

Short interest Falling

10.28% of float · ▼ -4.6% MoM · 11.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

176 holders — near 2-yr high, broad support

Price context

position in its 52-week range

Range low $10 Now $63 · 87% Range high $71

vs 200-day avg +58% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
cash, cash equivalents and marketable securities	$373.7M	as of December 31, 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
MBX MBX Biosciences, Inc. this stock	$3.20B	+99.7%	—	—	10.3%
VRTX Vertex Pharmaceuticals Inc / Ma	$137.30B	+19.5%	+46.2%	31.6	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$81.27B	+2.9%	+20.8%	19.6	2.3%
ARGX Argenx SE	$63.63B	+21.7%	—	—	1.9%
CSLLY Csl Ltd	$59.23B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

176

% held: 116.4%
Net QoQ: +3.4M sh
Top holder: Frazier Life Sciences Man…

Held Float

View

Held by Funds

Fund positions

187

View

Short & Settlement

Short Interest Falling

Shares short

5.0M

Days to cover: 11.2d
Change: -238.5K sh

View

Short Volume

Short vol %

59%

As of: Aug 28, 2026

Short Total

View

Fails to Deliver

FTD shares

2.3K

Value: $142.5K
As of: Jul 27, 2026

View

Off-Exchange

Off-exchange %

46.8%

Week of: Jul 20, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$24.3K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Net income (FY)

$-87.0M

EPS diluted: $-2.38

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 27, 2026
This year: 20

View

Proposed Sales

Value

$255.7K

Shares: 3.7K
Filed: Aug 17, 2026

View

Exempt Offerings

Offering

$115.2M

Filed: Nov 18, 2022

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

Performance

	5D	20D	120D	MTD	YTD
MBX	-5.0%	-4.4%	+125.5%	-4.4%	+99.8%
SPY	+0.5%	+3.0%	+13.4%	+3.0%	+12.8%
vs SPY	-5.5%	-7.4%	+112.1%	-7.4%	+86.9%

Key facts CIK 1776111 CUSIP 55287L101 13F (30d) 159 filings 155 filers Visit website Investor relations

MBX · MBX Biosciences, Inc.

Price & Indicators

Up next

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance